Two injections, two different problems in the same joint

Patients searching for a knee injection often frame the decision as a straight choice between two products. ChondroFiller and Arthrosamid are, in fact, treatments for two different problems that happen to share a postcode — the knee joint.

The knee contains distinct structures. Articular cartilage coats the ends of the femur and tibia, forming the load-bearing surface where bone meets bone. The synovial membrane is a separate tissue: a soft lining that encases the joint cavity and produces lubricating fluid. These two structures can fail independently, and they require different interventions.

ChondroFiller is an injectable collagen scaffold indicated for focal articular cartilage defects — discrete areas of damage, typically Grade II or III, up to roughly 2.5–3 cm² in size, caused by trauma or early localised wear. It is a regenerative treatment: once placed under ultrasound guidance, it forms a biodegradable matrix that recruits the patient's own progenitor cells to support endogenous cartilage repair over 12–24 months.

Arthrosamid is a synthetic polyacrylamide hydrogel that, after injection, permanently integrates into the synovial lining. It does not repair cartilage. Its role is mechanical cushioning and symptom relief in diffuse knee osteoarthritis, where the pattern of wear is generalised rather than focal.

In published clinical studies, hyaluronic acid (viscosupplementation) has served as the main comparator for both products separately; no head-to-head randomised trial between ChondroFiller and Arthrosamid exists. The practical implication is straightforward: the question is not which injection is better — it is which diagnosis is present. That determination rests on MRI findings, not on symptom severity alone, and it should precede any treatment decision.

ChondroFiller: a scaffold for focal cartilage damage

The mechanism behind ChondroFiller — termed acellular matrix-induced chondrogenesis — is what sets it apart from other intra-articular injections. Delivered as an ultrasound-guided outpatient injection, the collagen hydrogel solidifies within three to five minutes of contact with the joint environment, forming a stable three-dimensional scaffold. The scaffold itself contains no cells; it provides a structure that draws the patient's own progenitor cells from the surrounding synovium and subchondral bone, guiding them to mature and deposit new cartilage matrix over 12–24 months. This is endogenous repair supported by a biodegradable framework — not cartilage injected from outside.

The process takes time. Functional improvement typically begins at six to twelve weeks, with continued scaffold maturation through the second year. Patients should not expect the kind of rapid symptom relief associated with a corticosteroid injection.

Who it is designed for

ChondroFiller is indicated for focal, contained cartilage lesions — typically Grade II or III, up to approximately 2.5–3 cm² — with healthy surrounding cartilage at the margins. It is not appropriate where the joint has diffuse wear, significant bone loss, or advanced osteoarthritis: the scaffold depends on viable adjacent tissue to integrate and mature correctly.

What the clinical data show

Across four clinical studies — all conducted within a manufacturer-sponsored framework, and without a large-scale independent RCT to date — IKDC scores improved by approximately 30 points at 12 months, consistently exceeding the minimal clinically important difference of 16.7 points (the threshold at which patients notice a meaningful change in knee function). The Jerosch prospective cohort recorded a mean gain of 32.4 points sustained to three years, with patients reaching a functional IKDC score of 80. MRI repair quality, measured by MOCART scoring, reached 81.6–84.3 at one year — confirming greater than 80% defect filling and good structural integration with surrounding native cartilage. More than 20,000 implantations have been recorded since the injectable form received its CE mark in 2013, with a reported adverse event complaint rate of approximately 0.06%.

Arthrosamid: a permanent cushion for osteoarthritic knees

Unlike the scaffold approach described above, Arthrosamid's role is mechanical, not regenerative. A single injection of this 97.5% water, 2.5% cross-linked polyacrylamide hydrogel (iPAAG) into the knee joint is intended to provide lasting cushioning — and once placed, it remains permanently integrated into the joint lining.

How integration works

After injection, synovial cells begin to proliferate into the hydrogel within 10–14 days, eventually forming a stable sub-synovial layer traversed by thin connective tissue strands. The literature characterises this process as a low-level macrophage-driven foreign body response — in plain terms, the body incorporates the gel into the joint lining rather than rejecting it outright. The result is a permanent elastic layer within the synovium that may reduce intra-articular mechanical stress and inflammation. Arthrosamid is indicated for diffuse knee osteoarthritis and has no role in treating focal cartilage lesions.

Duration of effect

The most durable data available come from a five-year extension study of 49 patients given a single 6 mL injection, of whom 27 completed the full follow-up period. Sustained, statistically significant WOMAC improvements were recorded across pain (−14.6 points), stiffness (−19.6 points), and physical function (−12.5 points) through year five — the longest single-dose durability evidence currently published for any knee injection. The small completion cohort (27 of 49) should temper how much certainty is read into those numbers.

A 24-month real-world cohort of 314 knees adds useful context on who responds best: lower Kellgren-Lawrence OA grade, older age, absence of diabetes, and bilateral disease were independent predictors of meaningful improvement. Of the 49 patients who ultimately required total knee replacement during follow-up, most had higher-grade disease at baseline — evidence that Arthrosamid does not halt OA progression and works best before the joint reaches end-stage degeneration. Complications were recorded in 155 of 314 knees; available source material does not detail their nature or severity.

Permanence and open regulatory questions

Because the hydrogel integrates into the synovial lining, it cannot be dissolved, metabolised, or withdrawn. Regulatory authorities have formally debated whether iPAAG should be classified as a medical device or a pharmaceutical product — a distinction that determines the depth of safety evidence required before approval. Within that regulatory debate, the potential for a permanent PAAG implant to leach unreacted acrylamide monomer over a patient's lifetime has been specifically raised as a concern: acrylamide is classified as a neurotoxin and a probable human carcinogen. This is not a reported clinical event from the available studies, but neither were those studies designed or powered to detect rare toxicological signals. It remains an open and unresolved question in the regulatory literature.

Timeline and what recovery looks like for each

ChondroFiller follows the pace of biology, not pharmacology. Most patients notice the first functional gains between six and twelve weeks — not because pain relief has been injected in, but because the scaffold has begun to attract and organise the patient's own repair cells. Maturation continues through twelve to twenty-four months; the collagen framework gradually biodegrades as new cartilage-like tissue takes its place. Patients should expect reduced impact activity during early scaffold maturation — the precise loading guidance will be discussed at the treating clinic — and should plan for the repair arc to run across roughly two years before the full benefit is apparent.

Arthrosamid moves more quickly. Synovial cell ingrowth into the gel begins within ten to fourteen days of injection, and most patients report meaningful symptomatic improvement as the cushioning layer establishes. Because the gel is permanent — already established in s3 above as non-dissolvable — the practical implications extend beyond the initial recovery window. Any future intra-articular procedure, including total knee replacement if the disease progresses, must take the integrated hydrogel into account. The joint will need careful pre-operative assessment, and the operating team should be informed of its presence. Ongoing monitoring of symptoms and joint status is therefore part of the long-term commitment to this treatment, not an afterthought.

Both treatments are privately funded, with no current NHS pathway — a relevant planning consideration that sits alongside these timelines when weighing options at consultation.

How to decide — and when both might be relevant

The diagnosis is the decision. Before weighing up products, specialist assessment — ideally with MRI — is needed to establish what the knee actually shows: a contained focal cartilage lesion, diffuse osteoarthritis with synovial involvement, or elements of both.

Where MRI reveals a focal, contained defect with healthy surrounding cartilage borders, ChondroFiller sits within the appropriate part of the treatment landscape. That scaffold approach is designed for a localised, structurally specific presentation — not for the joint-wide wear pattern of osteoarthritis.

Where the picture is diffuse OA — widespread synovial involvement, global cartilage thinning, no discrete focal lesion — Arthrosamid addresses that environment through durable cushioning rather than tissue repair.

Timeline tolerance shapes the conversation too. ChondroFiller's benefit arc runs across twelve to twenty-four months; Arthrosamid's cushioning layer establishes within weeks of injection. A patient who needs meaningful near-term symptom relief while a longer structural process matures is a different candidate from one who can commit to a slow-build regenerative trajectory.

When both pathologies coexist, the two products may have a complementary role. A knee with a discrete focal defect sitting within a broader osteoarthritic environment could, in principle, be treated with ChondroFiller as the regenerative scaffold component and Arthrosamid as the cushioning component — mechanisms that are additive rather than redundant. This is not a standard protocol; it is a clinically considered option for specific dual-pathology presentations and requires specialist evaluation on a case-by-case basis.

Arthrosamid's permanence adds a further consideration: if total knee replacement becomes necessary later, the integrated hydrogel must be accounted for in pre-operative planning. That factor belongs in the decision-stage conversation, not as an afterthought once the injection has been given.

Neither product replaces appropriate physiotherapy, weight management, or surgical intervention where those are indicated. Both sit within a broader care pathway — not in place of it.

Getting the right diagnosis at Lincolnshire Knee

The diagnostic question comes before the product question. Whether ChondroFiller, Arthrosamid, or an alternative is appropriate depends entirely on what a thorough knee assessment reveals: defect size and containment, Kellgren-Lawrence OA grade, synovial status, and the patient's functional baseline. MRI is the central investigation — without characterising these features, distinguishing a focal cartilage lesion from diffuse osteoarthritic change is unreliable, and the injection choice follows directly from that distinction.

Advanced MRI analysis — including cartilage segmentation and T2 mapping — can resolve defect depth and surrounding tissue quality with greater precision than standard radiological reporting, which matters when the treatment decision turns on whether a lesion is truly contained or part of broader joint deterioration. Objective biomechanical assessment, such as gait analysis using validated biomarker protocols, adds functional data that imaging alone cannot capture and informs realistic rehabilitation planning alongside any injection.

All injection treatments in this comparison — ChondroFiller, Arthrosamid, and alternatives — are delivered as ultrasound-guided outpatient procedures; none require surgical admission or general anaesthesia.

Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral. Assessments are available at Sleaford NG34 and Grantham NG31. Book at lincolnshireknee.co.uk.

1. [1] Polyacrylamide hydrogel injections in knee osteoarthritis: A PROMs-based 24 month cohort study. (2025). https://doi.org/10.1016/j.jcot.2025.103136 https://doi.org/10.1016/j.jcot.2025.103136
2. [2] A prospective, open-label, clinical investigation of a single intra-articular polyacrylamide hydrogel injection in participants with knee osteoarthritis: a 5-year extension study. (2025). https://doi.org/10.1186/s13018-025-06526-0 https://doi.org/10.1186/s13018-025-06526-0